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Background: Hyponatremia is a well-known adverse event of repeated therapy with
vincristine in oncological patients. However, to date, data in pediatric patients with
malignant diseases other than acute lymphoblastic leukemia (ALL) are sparse or lacking.
Materials and Methods: A retrospective study of 98 pediatric patients was conducted
to analyze the incidence of hyponatremia in a Caucasian cohort of newly diagnosed ALL.
For comparison, we further examined five other pediatric oncological cohorts (Hodgkin’s
disease, Ewing sarcoma, Wilms tumor, benign glioma of the CNS, Langerhans cell
histiocytosis) that receive alkaloids in their induction regimes.
Results: We found a high incidence of hyponatremia (14.7%) in our ALL cohort with a
trend toward male patients of elementary school age. None of the affected patients
showed neurological symptoms. By comparison, patients from other malignancy groups
did not show significant hyponatremia, regardless of their comparable therapy with
alkaloids. We here show a noticeable coincidence of hyponatremia and
hypertriglyceridemia in ALL patients, indicating a possible role of L-asparaginase-related
hypertriglyceridemia in the development of severe hyponatremia in such patients.
Conclusion:We report a higher incidence of hyponatremia following vincristine therapy in
Caucasian children with ALL than published before. This hyponatremia could not be
demonstrated in other oncologic cohorts treated with alkaloids. L-Asparaginase-induced
hypertriglyceridemia may play a role in the certainly multifactorial development of
hyponatremia in childhood leukemia.
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Hyponatremia is an electrolyte disturbance commonly seen in
clinical practice. Its etiology is heterogeneous. The syndrome of
inappropriate secretion of antidiuretic hormone (SIADH) is the
most common underlying cause. It can occur as a paraneoplastic
phenomenon, as a result of central nervous system (CNS) lesions
(intracranial tumor masses or metastatic lesions, meningitis, or
cranial irradiation) or of pulmonary disease (pneumonia,
metastasis), or as an adverse effect of anticancer therapy
(1–4). Among vinca alkaloids, vincristine and, to a lesser
extent, vinblastine have been frequently reported to trigger
hyponatremia in oncological patients through a direct neurotoxic
effect on sites in the hypothalamus, the neurohypophyseal
tract, or the posterior pituitary gland (5–20). This neurotoxic
effect of vincristine has also been demonstrated in animal models
(21, 22). Vinca alkaloids are indicated for the treatment of a
variety of pediatric oncological diseases, among them acute
lymphoblastic leukemia (ALL), Hodgkin’s or non-Hodgkin’s
lymphoma, sarcoma, and some other tumor entities. Severe
hyponatremia of rapid onset (<48 h) is a medical emergency
that can lead to serious neurological complications, which may
be therapy-delaying or even life-threatening. Only sparse data
address hyponatremia during intensive therapy of pediatric
oncological patients. In this retrospective study, we focus on
the occurrence of severe hyponatremia during induction
chemotherapy with vinca alkaloids in a pediatric Caucasian
cohort of ALL patients. For comparison, we analyze five
additional similarly treated cohorts of pediatric patients with
oncological diagnoses other than ALL.MATERIALS AND METHODS
Patients Included in the ALL-BFM 2009
Protocol
The retrospectively evaluated principal cohort included 98
children and adolescents (age >1 year to <18 years) with ALL
newly diagnosed at our institution (Department of Pediatrics I,
Medical University of Innsbruck) between December 2010 and
January 2019. Three patients were excluded from analysis
because transfer to another hospital resulted in absence of
serum sodium values for at least 10 consecutive days. Of the
remaining 95 patients, 56 were male (58.9%) and 39 were female
(41.1%). The mean age at diagnosis was 6.3 years (range 1.1 to
17.9 years, see also Table 1). All patients received chemotherapyFrontiers in Oncology | www.frontiersin.org 2according to the ALL-BFM 2009 protocol (Figure 1A, https://
www.clinicaltrialsregister.eu/ctr-search/trial/2007-004270-43/
DE). Relevant for this study is the weekly intravenous
administration of vincristine during induction therapy (four
doses, starting on day 8).
All high-risk patients received antifungal prophylaxis with
liposomal amphotericin-B instead of formerly used azoles.
Patients not meeting criteria for high-risk status received no
routine fungal prophylaxis at all.
Patients Included in Therapy Protocols
Other Than ALL-BFM 2009
Additionally, for comparison, we retrospectively analyzed five
pediatric oncological cohorts in which patients received
vincristine (or vinblastine) during their first weeks of
treatment: 28 patients with newly diagnosed Hodgkin’s disease
included in the EuroNet-PHL-C2 and the GPOH Register
therapy protocol (Figure 1B, OEPA scheme); 23 patients with
newly diagnosed Ewing sarcoma enrolled in the EuroEWING
2008 protocol (Figure 1C, VIDE cycle); 20 patients with Wilms
tumor during preoperative chemotherapy (Figure 1D, SIOP
2001 Wilms/SIOP 2014 Wilms Register); 16 patients with
initial diagnosis of a benign glioma of the CNS (Figure 1E,
SIOP-LGG 2004); and 9 patients with Langerhans cell
histiocytosis (Figure 1F, LCH-III/-IV). For information on the
general statistics, age distribution, and gender distribution of
these patient groups, see Table 1.
During the first days of induction chemotherapy, to prevent
tumor lysis syndrome, all newly diagnosed patients with great
tumor burden (especially those with ALL, Hodgkin’s disease,
Ewing sarcoma, or Wilms tumor) received hydration therapy
consisting of a semi-isotonic solution (50% NaCl 0.9%, 50%
glucose 5%, 40 ml/l sodium bicarbonate) administered
intravenously at 3 l/m2/24 h.
Laboratory Methods
Routine blood specimens for electrolyte determinations were
drawn daily or at least every 2 to 3 days during induction
chemotherapy (first 40 days). If hyponatremia was detected,
blood specimens were drawn at least twice a day or even more
often until serum sodium values normalized. Serum sodium was
detected by indirect potentiometry in our central laboratory
(Innsbruck Medical University Hospital). The standard range
of serum sodium in a healthy child is 132 to 145 mmol/l (23).
Severe hyponatremia (a “hyponatremic episode”) was defined
as a serum sodium level ≤130 mmol/l on at least 2 of 3
consecutive days.TABLE 1 | General statistical information on patients included in the analyzed studies (age and gender distributions).
Diagnosis Inclusion period No. of patients Male Female Age at diagnosis
ALL cohort 12/2010–01/2019 95 (3/98 excluded) 56 (58.9%) 39 (41.1%) 6.3 years (1.1–17.9)
Hodgkin’s disease From 08/2013 (still open) 28 (2/30 excluded) 12 (42.9%) 16 (57.1%) 13.5 years (5.0–18.0)
Ewing sarcoma 05/2010–06/2019 23 11 (47.8%) 12 (52.2%) 11.9 years (3.0–18.1)
Wilms tumor From 10/2010 (still open) 20 6 (30.0%) 14 (70.0%) 3.5 years (0.5–14.8)
Benign CNS glioma From 04/2004 (still open) 16 (1/17 excluded) 7 (43.8%) 9 (56.2%) 3.6 years (0.4–11.5)
Langerhans cell histiocytosis From 04/2001 (still open) 9 5 (55.6%) 4 (44.4%) 5.1 years (0.2–11.6)October 2021 | Volume 11 | Article 708875
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Analysis of primary study endpoints was performed with
descriptive and inferential statistics. The measured sodium
values of all patients on a particular day of treatment were
summarized in two calculated values for that day: the
minimum sodium values of all patients were averaged (= MIN)
as were the mean sodium values of all patients (= MEAN).
However, not every patient necessarily had a sodium value on
every single day. On the other hand, some patients had two orFrontiers in Oncology | www.frontiersin.org 3more sodium values on some days. The measuring dots in the
diagrams (Figure 2) thus result from the above-indicated day/
MIN pairs and day/MEAN pairs (for both hyponatremic and
non-hyponatremic patients). Data analysis and statistical tests
were performed with a C++ program (version C++17).
Statistically significant differences between the sodium levels of
hyponatremic and non-hyponatremic patients were determined
with statistics F tests and subsequent T tests for all days of






FIGURE 1 | Induction therapy protocols using vincristine or vinblastine: (A) ALL cohort: ALL-BFM 2009 (Protocol I, induction), (B) Hodgkin’s cohort: EuroNet-PHL-
C2 protocol and GPOH Register (OEPA scheme), (C) Ewing sarcoma cohort: EuroEWING 2008 (VIDE cycle), (D) Wilms tumor cohort: SIOP 2001 Wilms and SIOP
2014 Wilms Register (preoperative chemotherapy), (E) benign CNS glioma cohort: SIOP-LGG 2004, and (F) Langerhans cell histiocytosis cohort: LCH-III and LCH-IV protocol.October 2021 | Volume 11 | Article 708875
Salvador et al. Hyponatremia in Pediatric OncologyA
B
FIGURE 2 | (A) Prevalence of hyponatremia in the studied ALL cohort: a considerable group of ALL patients showed statistically significant hyponatremia during
induction therapy (solid line, ± standard deviation) compared to the rest of the ALL cohort (dashed line), which remained within the standard range of sodium in
childhood (132–145 mmol/l). The start of the first hyponatremic episode was on average between days 27 and 28 (average day 27.6, curly brackets), although there
was a statistically significant difference between hyponatremic and non-hyponatremic patients from day 12 (p = 0.014, F test and T test, curly brackets). (B) Mean
sodium levels of all patients with the following diagnoses during the first 40 days of their initial therapy. Patients with Hodgkin’s lymphoma, Ewing sarcoma, Wilms
tumor, benign brain tumors, and Langerhans cell histiocytosis do not show hyponatremia during therapy with alkaloids (sodium levels within standard range).Frontiers in Oncology | www.frontiersin.org October 2021 | Volume 11 | Article 7088754
Salvador et al. Hyponatremia in Pediatric Oncologydifferences between the mean values were calculated. Statistical
associations between hyponatremia and, individually, age,
gender, CNS status, high-risk status, hypertriglyceridemia, and
hyperglycemia were calculated using Fisher’s exact test. p values
below 0.05 were deemed statistically significant. Graphic
presentation was performed with LaTeX (version TeX
Live 2020).
Ethics
The Ethics Committee of the Medical University of Innsbruck
approved the retrospective evaluation (EC No. 1477/2020). All
data were obtained from medical records. This study was
performed in accordance with the Declaration of Helsinki.Frontiers in Oncology | www.frontiersin.org 5RESULTS
Statistically Significant Severe
Hyponatremia in Caucasian Children
With ALL
The incidence of severe hyponatremia during ALL-BFM 2009
induction therapy was 14.7% (14/95 cases, Table 2) in our
Caucasian cohort, a value higher than those reported for
pediatric ALL cohorts (24, 25). The difference between
hyponatremic and non-hyponatremic patients was statistically
significant from day 12 after the start of therapy (Figure 2A,
day 12, p = 0.014, Supplemental Table). The average age of
hyponatremic patients was 9.0 (range 2.2–17.9) years, whereasTABLE 2 | Prevalence of hyponatremia in the examined ALL cohort (14.7%).
Relevant factors Hyponatremia Normal sodium level Fisher’s exact test
ALL cohort 14/95 (14.7%) 81/95 (85.3%)
Age group
< 5 years 3/14 (21.4%) 47/81 (58.0%) p = 0.0369
5–10 years 7/14 (50.0%) 23/81 (28.4%)
10–13 years 0/14 (0.0%) 2/81 (2.5%)
>13 years 4/14 (28.6%) 9/81 (11.1%)
Average age (years) 9.0 (range: 2.2–17.9) 5.9 (range: 1.1–17.5)
Gender
Male 10/14 (71.4%) 46/81 (56.8%) p = 0.385
Female 4/14 (28.6%) 35/81 (43.2%)
CNS status
Negative 12/14 (85.7%) 76/81 (93.8%) p = 0.274
Positive 2/14 (14.3%) 5/81 (6.2%)
Risk group
Non-high risk 9/14 (64.3%) 65/81 (80.3%) p = 0.292
High risk 5/14 (35.7%) 16/81 (19.7%)
Triglycerides
>1000 mg/dl 6/14 (42.9%) 4/81 (4.9%)
p = 0.000177>500 mg/dl 1/14 (7.1%) 14/81 (17.3%)
Normal 3/14 (21.4%) 53/81 (65.4%)
No data available 4/14 (28.6%) 10/81 (12.4%)
Serum-protein
• During hyponatremia
> 8 g/dl 0/14 (0.0%) –
Normal 2/14 (14.3%) –
<5 g/dl 12/14 (85.7%) –
• After asparaginase
>8 g/dl 0/14 (0.0%) 0/81 (0.0%)
Normal 0/14 (0.0%) 24/81 (29.6%)
<5 g/dl 14/14 (100.0%) 57/81 (70.4%)
Serum-glucose
• During hyponatremia
>150 mg/dl 2/14 (14.3%) –
<150 mg/dl 12/14 (85.7%) –
• During induction therapy
>150 mg/dl 4/14 (28.6%) 28/81 (34.6%) p = 0.767
<150 mg/dl 10/14 (71.4%) 53/81 (65.4%)
}
October 2021 | VolumeVarious factors that could possibly be related to hyponatremia were examined for their statistical significance, namely, age, gender, CNS status, risk group, and relevant laboratory
parameters (serum-triglycerides, serum-protein, serum-glucose). We were able to show a trend to male patients of primary school age (age p = 0.0369, gender p = 0.385). Hyponatremia
is not associated with positive CNS status (p = 0.274) or high-risk disease (p = 0.292). Interestingly, a statistically significant coincidence of elevated triglycerides (>1000 mg/dl) and
hyponatremia during ALL induction therapy (p = 0.00017) was observed. At least 42.9% of hyponatremic patients showed massively elevated triglycerides during hyponatremia, whereas
only 4.9% of non-hyponatremic ALL patients showed hypertriglyceridemia. On the other hand, serum protein and serum glucose were not responsible for a possible pseudohyponatremia:
57/81 (70.4%) non-hyponatremic patients showed hypoproteinemia during induction therapy and 12/14 (85.7%) hyponatremic patients showed hypoproteinemia at the time
of hyponatremia. No patient was observed with hyperproteinemia. Regarding serum glucose, we found 28/81 (34.6%) non-hyponatremic patients with hyperglycemia during
induction therapy and only 2/14 (14.3%) hyponatremic patients with glucose levels >150 mg/dl at the time of hyponatremia. Therefore, hyperglycemia is not associated with
hyponatremia (p = 0.767).11 | Article 708875
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years, range 1.1–17.5). Divided according to age groups, three
hyponatremic patients (21.4%) were aged <5 years, 7 (50%) 5–10
years, none 10–13 years, and 4 (28.6%) >13 years. Hyponatremic
patients were significantly older than non-hyponatremic
patients (p = 0.0369, Table 2). Furthermore, 10 (71.4%) of the
14 hyponatremic patients were male, while only 4 (28.6%,
Table 2) were female. However, no statistically significant
difference could be shown regarding gender (p = 0.385, Table 2).
The lowest sodium level measured was 123 mmol/l in one
patient. Of our hyponatremic patients, 71.4% (10/14) had only
one hyponatremia episode throughout induction therapy. One
patient had two episodes, another had three, and two each had
four episodes during induction. The first hyponatremic episode
started on average between days 27 and 28 (average day 27.6) but
occurred earlier or later in some patients (ranging from day 12 to
day 39 after start of therapy). A significant difference from non-
hyponatremic patients thus was demonstrated as early as day 12
(Figure 2A, p = 0.014, Supplemental Table). The median
duration of hyponatremia episodes was 3 days (median, range
2–6 days).
No Statistically Significant Occurrence of
Hyponatremia Episodes During Induction
Therapy in Patients Other Than the
ALL Group
For comparison, we analyzed other cohorts of pediatric patients
with newly diagnosed hemato-oncological diseases, all of whom
received vinca alkaloids (vincristine or vinblastine) in their first
weeks of induction therapy (Figures 1B–F). Dosage regimens
deviated somewhat from the usual schedule of weekly vincristine
doses: Patients with Ewing sarcoma received only one dose of
vincristine at the start of therapy, and patients with Langerhans
cell histiocytosis were treated with weekly vinblastine instead of
vincristine. We found that patients with Ewing sarcoma, Wilms
tumor, or Langerhans cell histiocytosis did not show any sodium
disturbances during their induction therapy (Figure 2B, mean
sodium levels remained within the standard range; see also
Table 3). In the patient cohorts with Hodgkin’s lymphoma
and benign tumors of the CNS, one patient each was detected
with one episode of hyponatremia (Table 3). In the Hodgkin’s
group, the single hyponatremic patient was a 5-year-old girl, and
in the cohort with benign CNS glioma the single patient was a
1.7-year-old boy.Frontiers in Oncology | www.frontiersin.org 6Association Between Severe
Hyponatremia and Other Relevant
Factors in ALL Patients
We were not able to prove a statistically significant association
between hyponatremia and CNS ALL involvement (p = 0.274) or
between hyponatremia and high-risk status (p = 0.292, Table 2).
Interestingly, a relatively high percentage of hyponatremic patients
(42.9%, 6/14) showed significantly increased serum triglyceride
values (>1,000 mg/dl) simultaneously with the hyponatremic
episode, whereas only 4.9% (4/81) of non-hyponatremic ALL
patients had triglyceride values >1,000 mg/dl during induction
therapy. This established a statistically highly significant association
between hyponatremia and hypertriglyceridemia in our ALL
cohort (p = 0.00017, Table 2). We infer that some instances of
hyponatremia thus may have been diagnosed because of an artifact
of measurement, representing “pseudohyponatremia.” Other
possible reasons for the development of pseudohyponatremia,
namely, hyperglycemia or hyperproteinemia, can be excluded in
our ALL cohort, because nearly all hyponatremic ALL patients had
normal serum glucose levels at the time of hyponatremia (12/14
patients had normal glucose levels, 2/14 had only slightly increased
serum glucose, Table 2, p = 0.767) and a high percentage showed
reduced serum protein values, with serum protein levels <5 g/dl in
12/14 (85.7%) hyponatremic patients (Table 2) but no
hyperproteinemia during hyponatremia.
Clinical Presentation of Hyponatremic
Patients
Clinically, our hyponatremic patients had no relevant serious,
especially neurological, complications. Relatively nonspecific
side effects such as lethargy or weakness during intensive
induction chemotherapy are difficult to attribute exclusively to
hyponatremia and can have various other causes, both therapy-
and illness-related. Of the patients with hyponatremia, 57.1% (8/
14) did not require any electrolyte or infusion therapy because
they lacked symptoms or signs; their “illness” was self-limited.
Three hyponatremic patients (21.4%) received one or at most
two isotonic infusions in a maintenance dose. Following a very
rapid decline in serum sodium levels, the final three patients
received sodium chloride 1 M (molar) as a substitute for sodium
at a dose of 1 mmol/kg as an isotonic infusion for 1 day each in
the absence of neurological symptoms. No patient underwent
fluid restriction in our hyponatremic cohort.DISCUSSION
Electrolyte disturbances are common during cytotoxic therapy of
malignant diseases. Some chemotherapeutic agents trigger
hyponatremia, with SIADH invoked. Implicated are vinca
alkaloids (vincristine, vinblastine), cyclophosphamide,
ifosfamide, and platinum-based drugs as well as monoclonal
antibodies and small-molecule inhibitors (6, 26, 27). Only a few
reports exist of marked hyponatremia associated with anti-
neoplastic therapy in children. A retrospective study from
Poland identified severe hyponatremia in 11.9% of a cohort ofTABLE 3 | Difference between ALL patients and patients with other diagnoses
studied in this study (Hodgkin’s disease, Ewing sarcoma, Wilms tumor, benign
CNS glioma, and Langerhans cell histiocytosis) regarding occurrence of
hyponatremia during induction chemotherapy.
Hyponatremia Normal sodium level
ALL cohort 14/95 (14.7%) 81/95 (85.3%)
Hodgkin’s disease 1/28 (3.6%) 27/28 (96.4%)
Ewing sarcoma 0/23 (0.0%) 23/23 (100.0%)
Wilms tumor 0/20 (0.0%) 20/20 (100.0%)
Benign CNS glioma 1/16 (6.3%) 15/16 (93.7%)
Langerhans cell histiocytosis 0/9 (0.0%) 9/9 (100.0%)October 2021 | Volume 11 | Article 708875
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regimens, which included vinca alkaloids (24). A prospective
study from India identified marked hyponatremia/SIADH in
10.8% of a cohort of children with acute lymphoblastic leukemia
treated with vincristine (25). In our retrospective study, we
analyzed a cohort of 95 children with ALL who were
uniformly treated with vincristine once a week for 4 weeks
(ALL-BFM 2009 protocol; Figure 1A). Severe hyponatremia
occurred in 14.7% overall (Table 2), a rate higher than those
in the cohorts from Poland (11.9%) (24) and India (10.8%) (25).
The average age of hyponatremic patients was 9.0 years; the
average age of non-hyponatremic patients was lower (5.9 years).
Hyponatremic patients thus were significantly older than non-
hyponatremic patients (p = 0.0369, Table 2). Divided according
to age groups, three hyponatremic patients (21.4%) were aged <5
years, 7 (50%) 5–10 years, none 10–13 years, and 4 (28.6%)
>13 years.
In addition, 10 of the 14 hyponatremic patients were male
(71.4%), a proportion seemingly at substantial variance with that
in our cohort overall (56 of 95; 58.9%). However, within the
cohort as a whole no statistically significant difference could be
shown regarding gender (p = 0.385, Table 2), which may reflect
the general preponderance of males among ALL patients (28).
Our study nonetheless suggested increased susceptibility to
hyponatremia among males of primary school age. We did not
identify the predisposition for hyponatremia among girls aged
>10 years reported from India (25).
Published data on the incidence of hyponatremia in pediatric
oncological practice are limited to children with ALL, even
though vincristine is also used in other pediatric tumors. As
several reports ascribe severe hyponatremia in oncological
patients to vinca-alkaloid therapy (6, 12, 13, 16, 17, 20), we
investigated whether this held for non-ALL patients, on whom
reports are sparse, particularly in children (4), as with a case
study of a 4-year-old boy with Wilms tumor and severe
symptomatic hyponatremia and seizures after vincristine
administration (29). Our study is the first to compare
incidence of hyponatremia in patients with various pediatric
tumors treated with alkaloids. We found that therapy-associated
hyponatremia is unique to ALL, as episodes of hyponatremia
during induction therapy did not occur in statistically significant
numbers in patients with Ewing sarcoma (one vincristine bolus
at start of therapy), with Hodgkin’s lymphoma, Wilms tumor, or
benign CNS gliomas (weekly vincristine bolus during the first
weeks of therapy), or Langerhans-cell histiocytosis (weekly
vinblastine bolus during first weeks of therapy) (Figure 2B and
Table 3). Vinca alkaloids thus do not appear per se to suffice as
an etiology for hyponatremia.
What factors other than vinca alkaloids might contribute to
hyponatremia in ALL that are absent or irrelevant in other
malignancies? Janczar et al. reported an association between
hyponatremia with neurologic symptoms following vincristine
administration and CNS involvement with leukemia at
diagnosis. They emphasized the role of cytostatic therapy
rather than leukemia alone in severe hyponatremia, as no
hyponatremic episode occurred before treatment withFrontiers in Oncology | www.frontiersin.org 7vincristine began (24). However, we found no association
between leukemic CNS involvement and hyponatremia in ALL
patients, as only 2 of our 14 hyponatremic patients had with
blasts in cerebrospinal fluid at presentation (p = 0.274, Table 2).
Nor could we state that high-risk ALL potentiates the
development of hyponatremia during induction therapy, as
only 5 of our 14 hyponatremic patients met high-risk criteria
(35.7%, p = 0.292, Table 2).
We examined in our ALL cohort various biomarkers that
might reflect susceptibility to hyponatremia during vincristine
therapy. Serum sodium values may erroneously be assessed as
low in patients with hypertriglyceridemia, hyperproteinemia, or
hyperglycemia when sodium is measured using indirect
potentiometry (30–33). Most ALL patients in induction
therapy, however, show pronounced hypoproteinemia due to
diminution in protein synthesis associated with asparaginase
therapy (34). Of our hyponatremic patients, 85.7% (12/14)
showed pronounced hypoproteinemia (<5 g/dl) coincident
with hyponatremia; 70.4% (57/81) of our non-hyponatremic
patients had serum protein levels <5 g/dl during induction
therapy. No patient showed hyperproteinemia at that time
(Table 2). Moreover, only 2/14 (14.3%) hyponatremic patients
had hyperglycemia coincident with hyponatremia, whereas 28/
81 (34.6%) non-hyponatremic patients were hyperglycemic
during induction therapy (p = 0.767, Table 2). We thus infer
that hyperproteinemia and hyperglycemia were not responsible
for artifactual hyponatremia, viz., pseudohyponatremia, in our
ALL cohort. Interestingly, in 42.9% (6/14) of our hyponatremic
patients marked hypertriglyceridemia (>1,000 mg/dl) coincided
with hyponatremia (Table 2). In another, a lesser degree of
hypertr ig lycer idemia (<500 mg/dl) coincided with
hyponatremia. In 4 (28.6%) of our 14 hyponatremic patients,
no serum triglyceride values during induction therapy were
available. However, two of these four triglyceride values rose
markedly during reinduction therapy. We suspect that the
percentage of hyponatremic patients with hypertriglyceridemia
may have been higher than detected, especially in view of
evidence that the incidence of hypertriglyceridemia in ALL
patients is relatively high (35). As triglyceride values >1 000
mg/dl were seen in only 4.9% (4/81) of non-hyponatremic
patients, but in 42.9% (6/14) of hyponatremic patients
(Table 2), we could demonstrate a statistically highly
significant association between massive hypertriglyceridemia
and the occurrence of hyponatremia in ALL patients during
induction therapy (p = 0.00017, Table 2).
In our department, nearly all newly diagnosed patients,
especially those with great tumor burden (ALL, but also other
entities such as Hodgkin’s lymphoma, Wilms tumor, and Ewing
sarcoma), receive intravenous semi-isotonic hydration (see
Materials and Methods) as tumor lysis syndrome prophylaxis.
Administration of hypotonic maintenance fluids may be
associated with a greater risk for hyponatremia than is
administration of isotonic solutions (36–40). Hyponatremia in
our patients thus might conceivably have reflected serum
dilution. Against this are, first, that hyponatremia was seen
mainly in the ALL cohort and not in similarly treated patientsOctober 2021 | Volume 11 | Article 708875
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administered only for the first few days—up to at most 1 week—
after induction chemotherapy begins. However, hyponatremic
episodes were detected days later, as the decline in sodium levels
was statistically significant only from day 12 after therapy began
(Figure 2A, p = 0.014, Supplemental Table), precluding
dilutional artifact. Not only this: the prevalence of
hyponatremia is still high despite use of recommended isotonic
fluid regimes (41).
Certain medications used simultaneously with vinca alkaloids
may worsen the risk for hyponatremia in induction therapy for
ALL (27). However, hyponatremia has not yet been ascribed to
other cytostatic agents used during Protocol I of induction
therapy of the ALL-BFM 2009 study (Figure 1A). Known
possible potentiators are azole antifungals (itraconazole,
voriconazole, posaconazole, ketoconazole) (42–47). These
inhibit catabolism of vinca alkaloids, increasing exposure. Only
high-risk patients in our ALL cohort received antifungal
prophylaxis, however, and with liposomal amphotericin-B
rather than azoles. Azole potentiation of hyponatremia thus
cannot be invoked as contributory to hyponatremia in
our patients.
Nor can the type of therapy regimen with vinca alkaloids be
the only cause of the high incidence of hyponatremia in
childhood ALL. The weekly administration of 1.5 mg/m2/day
(maximum 2 mg) vincristine as an intravenous bolus is
absolutely comparable in dose and frequency to that used in
therapy regimens for other malignancies, regimens that in this
study were not associated with episodes of hyponatremia. The
first hyponatremic episode in our ALL cohort started on average
between days 27 and 28 (average day 27.6) but occurred earlier or
later in some patients (range from day 12 to day 39 after start of
therapy, Figure 2A). This is consonant with others’ observations,
which place the onset of hyponatremia approximately 7 days or
even longer after receiving vincristine intravenously (7, 9, 16, 48,
49). We propose, as suggested elsewhere (17), that development
of marked hyponatremia associated with vinca alkaloids
definitely requires repeated administration of vincristine. A
single dose may not be enough to cause severe hyponatremia
(for example, in patients with Ewing sarcoma).
In conclusion, we here show a substantial incidence of
hyponatremia in a pediatric ALL cohort during induction
chemotherapy with weekly administered vincristine.
Hyponatremic episodes were more likely in males of primary
school age. Occurrence of hyponatremia was not statistically
significant in cohorts of children with other malignancies and
comparable vinca-alkaloid therapy. None of our patients showed
hyponatremia-associated severe neurological symptoms or
complications, perhaps because sodium levels fell only moderately
(least observed, 123 mmol/l). In addition, some instances ofFrontiers in Oncology | www.frontiersin.org 8hyponatremia were certainly factitious (pseudohyponatremia), in
part an artifact of hypertriglyceridemia. This might explain our
patients’ lack of neurological complications. We accordingly
recommend that serum triglycerides be determined regularly
during ALL induction therapy to permit assessment of whether
hyponatremia is artifactual (and can be disregarded) or true (and
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